Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis Pharmaceuticals Announce First Product
Posted 12:01:00 08/20/2012 by Admin
IRVINE, CA, Aug 20, 2012 (MARKETWIRE via COMTEX) Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) cold remedy, are pleased to announce plans to introduce their first product offering since the creation of Itonis Pharmaceuticals, a division of Itonis. The new division will concentrate on marketing over-the-counter and prescription preparations to treat both common ailments and chronic diseases.
Over the coming weeks, Dr. Hensley and Itonis Pharmaceuticals will outline plans to introduce into the marketplace an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.
Dr. Hensley commented, "I consult for many corporations in the product development and strategic marketing arena but I am especially excited about leading the Itonis Pharmaceuticals team in bringing this product to market. I believe the time is right to begin introduction of what I believe will be a revolutionary product. There have been relatively few innovations within this product category over the past few years and we believe the market is ripe for a new type of nausea preparation that is available over-the-counter. We believe this new preparation will be both safe and effective for a wide range of nausea related conditions."
While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.
Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.
Dr. Hensley has joined the Itonis team to lead the Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is led by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States.
About Itonis, Inc. Itonis, Inc. (the Company) was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., and later changed its name to Itonis, Inc., on December 2, 2005. For more information, please visit www.itonisholdings.com.
Safe Harbor: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Stock Quote - ITNS
Investor RelationsItonis Holdings Company is a trade name of Itonis Inc. (OTC:ITNS), a publicly traded company.
Contact our office at (949) 200-8887 or email us at firstname.lastname@example.org for more information.
Latest Quarterly Reporthttp://www.otcmarkets.com/financialReportViewer?symbol=ITNS&id=180805